Company: ENTXW
Filing Date: 2025-06-05
Form Type: DEF 14A
Source: 0001178913-25-002111
Chunk: 69

Company: Entera Bio Ltd.
Filing Date: 2025-06-05
Form: DEF 14A
Chunk 69
---
 such that Ms. Yaacov-Garbeli will be fully vested in the total number of 2025 RSUs listed above as of 
 such applicable quarterly anniversary (i.e., such that one hundred percent (100%) of the 2025 RSUs shall become fully vested on April 28, 2026); provided further, however, that in the event of the Change in Control in which Ms.            
 Yaacov-Garbeli continues to provide services to the Company on the date of consummation of such Change in Control, 100% of any unvested 2025 RSUs at the time of the consummation of such Change in Control shall become fully vested.         |

| (iii) | 2025 Cash Compensation Increase. Ms.Yaacov-Garbeli will be entitled to an annual cash consideration of $251,983 (the “Updated Cash Compensation”), effective as of April                                                           
 1, 2025, in accordance with the terms of her consulting agreement. For the avoidance of doubt, given the nature of her consulting agreement, the abovementioned Updated Cash Compensation reflects the full payment in cash to Ms. 
 Yaacov-Garbeli in consideration for her services, except for any reasonable out of pocket expenses which were pre-approved in writing in connection with her duties as Chief Financial Officer.                                    |

Proposal Shareholders are being asked to adopt the following resolution: “RESOLVED, that the revised compensation terms to Dana Yaacov-Garbeli, our Chief Financial Officer, as described in Proposal Four of the Company’s Proxy Statement for the Company’s 2025 Annual Meeting, be, and are hereby, ratified and approved.” Vote Required Proposal Four requires the affirmative vote of a simple majority of our Ordinary Shares voted in person or by proxy, meaning that more votes must be cast “for” than “against” for Proposal Four, and abstentions and broker non-votes have no effect on the outcome of Proposal Four. In addition to the simple majority vote described above, the Israeli Companies Law requires further, to the extent applicable pursuant to the provisions of the Israeli Companies Law, that either (i) such majority must include a simple majority of the votes cast by shareholders having no personal interest in the matter (excluding abstentions) or (ii) the total number of votes of shareholders mentioned in clause (i) above who voted against such transaction does not exceed 2% of the total voting rights in the company. As part of the Special Majority vote,